Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Operating Leases (2019 - 2025)

Agios Pharmaceuticals (AGIO) has disclosed Operating Leases for 7 consecutive years, with $26.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Operating Leases fell 56.39% year-over-year to $26.5 million, compared with a TTM value of $26.5 million through Sep 2025, down 56.39%, and an annual FY2024 reading of $40.2 million, down 29.45% over the prior year.
  • Operating Leases was $26.5 million for Q3 2025 at Agios Pharmaceuticals, down from $48.8 million in the prior quarter.
  • Across five years, Operating Leases topped out at $103.0 million in Q1 2021 and bottomed at $26.5 million in Q3 2025.
  • Average Operating Leases over 5 years is $67.8 million, with a median of $72.0 million recorded in 2022.
  • The sharpest move saw Operating Leases changed 0.0% in 2023, then crashed 56.39% in 2025.
  • Year by year, Operating Leases stood at $85.7 million in 2021, then decreased by 15.95% to $72.0 million in 2022, then decreased by 20.85% to $57.0 million in 2023, then fell by 29.45% to $40.2 million in 2024, then crashed by 34.02% to $26.5 million in 2025.
  • Business Quant data shows Operating Leases for AGIO at $26.5 million in Q3 2025, $48.8 million in Q2 2025, and $52.9 million in Q1 2025.